retatrutide mechanism of action retatrutide clinical trials 2024 2025 Diagram showing the of Retatrutide vs Survodutide: 24% vs

FDA-approved weight loss medications (semaglutide and tirzepatide) require either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia

These potential benefits, however, come with high costs that raise concerns about the impacts on public and private payers

Industry insiders also expect Novo Nordisk to follow with more price cuts next year to keep their rates close to generic prices with some premium

Phase 2 Metabolic Benefits Beyond weight loss, retatrutide improved cardiometabolic markers: Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose) Triglycerides: Reduced 27% from baseline Fasting glucose: Decreased 13.8 mg/dL HbA1c: Reduced 0.4% (in participants without diabetes) TRIUMPH-4: First Phase 3 Results (December 2025) TRIUMPH-4 was the first Phase 3 trial to report